Skip to main content

Table 3 Primary and Secondary Outcomes and Related Variables at Different Time Points in 2 Groups

From: Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients

 

Control Group

Ergocalciferol Group

p value Control vs ergo

Variable

Baseline

6 months

12 months

p for trend

Baseline

6 months

12 months

p for trend

Vitamin D level, ng/ml

19.2 ± 6.8

19.7 ± 8.3

14.2 ± 9.3

0.002

16.2 ± 7.5

29.5 ± 9.9

30.6 ± 11.7

<0.001

<0.001

EPO dose, IU X 103/month

26[12.3,49.4]

23.9[9.7, 42.2]

13[6.5,27]

0.01

27.5[13.2, 48]

26[16.4, 45.5]

23.4[9.5, 39]

0.02

ns

Hemoglobin, g/dl

11.2 ± 1.1

11.4 ± 1

10.7 ± 1.3

<0.001

11 ± 1.4

11.4 ± 1.5

10.9 ± 1.4

0.02

ns

TSAT, %

27.5 ± 10.1

31.6 ± 12.6

29.9 ± 10.9

0.03

34.7 ± 18

32.5 ± 12.2

31.7 ± 13.9

ns

0.02

Ferritin, mg/dl

538 ± 269

556 ± 260

614 ± 244

0.04

759 ± 425

691 ± 376

691 ± 370

ns

0.01

Albumin, mg/dl

4.2 ± 0.4

4.2 ± 0.2

4.2 ± 0.3

ns

4 ± 0.3

4.1 ± 0.3

4.3 ± 0.6

<0.001

<0.001

Iron sucrose, mg/month

260 ± 272

164 ± 151

199 ± 274

0.03

194 ± 231

180 ± 173

143 ± 162

ns

ns

Paricalcitol dose μg/month

26 [10.5, 42]

26[13, 51.5]

39[23.5, 52]

0.002

2512.5, 39]

24[12, 39]

20[9, 39]

ns

<0.001

Calcium, mg/dl

9.2 ± 0.7

9.2 ± 0.7

9.3 ± 0.8

ns

9.1 ± 0.7

9.4 ± 0.7

9.1 ± 0.8

<0.001

<0.001

Phosphorus, mg/dl

5.1 ± 1.4

5.6 ± 1.8

5.1 ± 1.3

0.01

5.3 ± 1.7

5.5 ± 1.7

5.7 ± 1.8

ns

0.03

PTH, pg/ml

283[162, 408]

253[151, 373]

257[160, 429]

ns

308[184, 490]

263[145, 416]

299[200, 471]

0.01

ns

Hospitalization n/year (%)

28 (35)

37 (35)

ns

  1. Data is presented either as mean ± SD or median [IQR] depending on the distribution